VCNX (Vaccinex) Accounts Receivable : $0.84 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Vaccinex Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Vaccinex's accounts receivables for the quarter that ended in Dec. 2024 was $0.84 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Vaccinex's Days Sales Outstanding for the quarter that ended in Dec. 2024 was 359.00.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Vaccinex's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was $-1.87.

Vaccinex Accounts Receivable Historical Data

The historical data trend for Vaccinex's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaccinex Accounts Receivable Chart

Vaccinex Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Receivable

Get a 7-Day Free Trial

0.16

0.18

0.96

0.84

Vaccinex Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Accounts Receivable	Get a 7-Day Free Trial															0.96	2.78	1.05	0.99	0.84

Vaccinex Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Vaccinex Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Vaccinex's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.838	/	0.213	*	91
=	359.00

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Vaccinex's accounts receivable are only considered to be worth 75% of book value:

Vaccinex's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(1.107	+	0.75 * 0.838	+	0.5 * 0	-	5.084
-	1.665	-	0)	/	2.677
=	-1.87

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Vaccinex Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Vaccinex's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaccinex Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaccinex Inc (OTCPK:VCNX) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

1895 Mount Hope Avenue, Rochester, NY, USA, 14620

Website

https://www.vaccinex.com

Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.

Executives

Albert Friedberg	director, 10 percent owner
Van Strydonck, Gerald E.	director	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Maurice Zauderer	director, 10 percent owner, officer: President and CEO	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Jacob B. Frieberg	director	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Elizabeth E. Evans	officer: Chief Operating Officer	C/O VACCINEX, INC., 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Robert Scala	officer: Chief Commercial Officer	1895 MT HOPE AVENUE, ROCHESTER NY 14620
Chrystyna Bedrij Stecyk	director	1895 MT. HOPE AVENUE, ROCHESTER NY 14620
Vaccinex, Inc.	director	1895 MOUNT HOPE AVE, ROCHESTER NY 14620
Jeff Goater	director	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Bala S Manian	director	1025 TERRA BELLA AVE, MOUNTAIN VIEW CA 94043
Barbara Yanni	director	1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Alejandro M. Berlin	director	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
John E. Leonard	officer: SVP, Development	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Ernest S. Smith	officer: SVP, Research & CSO	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Raymond E. Watkins	officer: SVP & Chief Operating Officer	1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620